ArticleNPJ science of food2026
Mechanistic study of FA-PG3 nanoparticles promoting adipose browning through the PPARγ and PRDM16-UCP1 pathway in severe pediatric obesity.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Food-derived bioactive compounds offer an attractive and sustainable approach to metabolic disease prevention, yet mechanistic evidence supporting their efficacy in pediatric obesity remains limited. This study investigates the thermogenic potential of ferulic acid (FA), a plant-derived phenolic compound, when delivered via a dendrimer-based nanocarrier. Using an integrative strategy combining network pharmacology, molecular docking, cellular assays, animal models, and clinical biomarker analysis, we demonstrate that FA-loaded generation 3 PAMAM nanoparticles (FA-PG3) effectively activate adipose tissue thermogenesis. Computational analyses identified UCP1 as a central molecular target of FA, with PPARγ and PRDM16 acting as critical upstream regulators. FA-PG3 nanoparticles exhibited optimized nanoscale properties and sustained FA release. In vitro, FA-PG3 promoted beige adipocyte differentiation, enhanced mitochondrial respiration, and increased thermogenic gene expression. In vivo, FA-PG3 improved energy expenditure, insulin sensitivity, and adipose browning in obese mice, while UCP1 silencing largely abolished these metabolic benefits. Notably, children with severe obesity exhibited significantly lower circulating levels of browning-associated adipokines, supporting the clinical relevance of targeting thermogenic pathways. Our findings highlight a previously underappreciated food-derived, nano-enabled strategy for metabolic reprogramming and position FA-PG3 as a promising translational candidate for addressing pediatric obesity through adipose tissue thermogenesis.
Identifiers
42315851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.